Literature DB >> 2317067

Pharmacokinetics of prednisolone in children with nephrosis.

P F Miller1, C J Bowmer, J Wheeldon, J T Brocklebank.   

Abstract

The pharmacokinetics of prednisolone given intravenously were studied in 11 children with relapsed steroid responsive nephrotic syndrome, and four control subjects. The clearance of both total and unbound drug was decreased in these children and the unbound fraction of the drug in plasma was significantly correlated with the degree of hypoalbuminaemia. We conclude that changes in the clearance of prednisolone and altered protein binding might account for some of the variability in both therapeutic responses and the incidence of toxicity in patients treated with standard dosage regimens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317067      PMCID: PMC1792212          DOI: 10.1136/adc.65.2.196

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

1.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

2.  Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome.

Authors:  N Ueda; M Chihara; S Kawaguchi; Y Niinomi; T Nonoda; J Matsumoto; M Ohnishi; T Yasaki
Journal:  J Pediatr       Date:  1988-01       Impact factor: 4.406

3.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

4.  Binding of prednisolone to alpha 1-acid glycoprotein.

Authors:  R L Milsap; W J Jusko
Journal:  J Steroid Biochem       Date:  1983-02       Impact factor: 4.292

5.  Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity.

Authors:  O C Green; R J Winter; F S Kawahara; L S Phillips; P R Lewy; R L Hart; L M Pachman
Journal:  J Pediatr       Date:  1978-08       Impact factor: 4.406

6.  Determination of prednisolone in plasma by high-performance liquid chromatography.

Authors:  R Hartley; J T Brocklebank
Journal:  J Chromatogr       Date:  1982-11-12

7.  Clinical pharmacokinetics in infants and children.

Authors:  A Rane; J T Wilson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission.

Authors:  G Gatti; E Perucca; G M Frigo; L D Notarangelo; L Barberis; A Martini
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression.

Authors:  S Leisti; O Koskimies
Journal:  J Pediatr       Date:  1983-10       Impact factor: 4.406

10.  The binding of prednisolone in human serum and to recrystallized human albumin in vitro.

Authors:  W H Steele; G M Hawksworth; H E Barber
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

View more
  4 in total

1.  Should we stop dosing steroids per body surface area for nephrotics?

Authors:  Guido Filler; Lisa A Robinson
Journal:  Pediatr Nephrol       Date:  2015-12-28       Impact factor: 3.714

2.  Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.

Authors:  Wei Zhao; Valéry Elie; Véronique Baudouin; Albert Bensman; Jean Luc André; Karine Brochard; Françoise Broux; Mathilde Cailliez; Chantal Loirat; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

3.  Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1.

Authors:  James C McCaffrey; Nicholas J Webb; Toryn M Poolman; Maryline Fresquet; Cressida Moxey; Leo A H Zeef; Ian J Donaldson; David W Ray; Rachel Lennon
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

Review 4.  Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.

Authors:  Anne M Schijvens; Rob Ter Heine; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2018-03-16       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.